Meeting
2012 ASCO Annual Meeting
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
Authors
Li Zhang
Sun Yat-sen University Cancer Center, Guangzhou, China
Li Zhang , Meiqi SHI , Cheng Huang , Xiaoqing Liu , Jian ping Xiong , Gongyan Chen , Wei Liu , Wenchao Liu , Yiping Zhang , Kai LI , Hao Yu , Haoyuan Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01270386
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7548)
DOI
10.1200/jco.2012.30.15_suppl.7548
Abstract #
7548
Poster Bd #
45F
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer.
First Author: Karen L. Reckamp
Poster
2021 ASCO Annual Meeting
Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.
First Author: Mingfang Zhao
Poster
2015 ASCO Annual Meeting
Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.
First Author: Yukio Hosomi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
First Author: Daisuke Kotani